Stockscreener 앱 받기
1.53
0.66%
0.01
전일 마감가:
$1.52
열려 있는:
$1.51
하루 거래량:
294.69K
Relative Volume:
0.18
시가총액:
$42.82M
수익:
-
순이익/손실:
$-64.47M
주가수익비율:
-0.2474
EPS:
-6.1852
순현금흐름:
$-52.33M
1주 성능:
+1.32%
1개월 성능:
-10.53%
6개월 성능:
-54.33%
1년 성능:
-71.35%
1일 변동 폭
$1.4801
$1.57
1주일 범위
$1.41
$1.675
52주 변동 폭
$1.39
$7.19
Jasper Therapeutics Inc Stock (JSPR) Company Profile
명칭
Jasper Therapeutics Inc
전화
(650) 549-1400
주소
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
JSPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
1.53 | 42.54M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-07-08 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-09-09 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-08 | 개시 | BTIG Research | Buy |
| 2024-06-27 | 개시 | Stifel | Buy |
| 2024-05-06 | 개시 | H.C. Wainwright | Buy |
| 2024-04-03 | 개시 | Evercore ISI | Outperform |
| 2024-03-28 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-18 | 개시 | TD Cowen | Outperform |
| 2023-08-11 | 개시 | CapitalOne | Overweight |
| 2022-02-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Credit Suisse | Outperform |
| 2021-10-21 | 개시 | William Blair | Outperform |
| 2021-10-20 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-13 | 개시 | Oppenheimer | Outperform |
모두보기
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
Rodman & Renshaw initiates Jasper Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Reach Out - ACCESS Newswire
HOKA Trail Shoe Guide: Is Jasper Therapeutics Inc. Equity Warrant stock attractive for long term wealth buildingBest Sellers Snapshot & walk-ready comfort choices - Улправда
Jasper Therapeutics reports updated data from briquilimab studies - Yahoo Finance
Jasper Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Sahm
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria - Sahm
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Connect - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Jasper Therapeutics appoints Jeet Mahal as CEO in leadership transition By Investing.com - Investing.com Nigeria
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria - TipRanks
Jasper Therapeutics Reports Positive Data from Briquilimab Studies - TradingView — Track All Markets
Jasper Therapeutics stock rises after leadership changes By Investing.com - Investing.com Australia
Jasper Therapeutics stock rises after leadership changes - Investing.com India
Jasper Therapeutics appoints Jeet Mahal as CEO in leadership transition - Investing.com
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of ... - Bluefield Daily Telegraph
Jasper Therapeutics, Inc. Announces Executive Changes - marketscreener.com
What analysts say about Jasper Therapeutics Inc stockTop Performing Stocks & Low Risk Trading Alerts - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
2025-12-28 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out | NDAQ:JSPR | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Earnings Notes - Trefis
Jasper Therapeutics (JSPR) Price Target Decreased by 15.25% to 13.09 - MSN
Evercore ISI Remains a Buy on Jasper Therapeutics (JSPR) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect - ACCESS Newswire
2025-12-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect | NDAQ:JSPR | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Jasper Therapeutics (NASDAQ:JSPR) Stock Price Down 7.3% – Time to Sell? - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Reach Out - ACCESS Newswire
Penny Stocks To Watch NowDecember 2nd - MarketBeat
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Jasper’s Stock Is In The Basement, But The Bet Is Binary - Finimize
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Reports Positive Phase 1b Study Results - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR) - The Globe and Mail
Jasper Therapeutics stock maintains Market Outperform rating at Citizens By Investing.com - Investing.com Canada
Jasper Therapeutics’ Briquilimab Program Shines Amid Financial Losses - StocksToTrade
Jasper Therapeutics, Inc. (JSPR) Stock: Surges as New Asthma Trial Data Shows Promising Results - parameter.io
Jasper Therapeutics’ Briquilimab: Stepping Up? - StocksToTrade
Can Jasper Therapeutics Deliver on New Studies? - timothysykes.com
$1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Anticipates Growth with Briquilimab Highlights - timothysykes.com
Why Is Jasper Therapeutics Stock Surging Tuesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Can Jasper Therapeutics’ Progress Propel Its Stock? - timothysykes.com
JSPR Explodes on Briquilimab Asthma Breakthrough - RagingBull
Jasper Therapeutics Inc (JSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):